多发性骨髓瘤(multiple myeloma,MM)为血液系统第二常见肿瘤,约占10%,起病隐匿,多发于中老年人,联合化疗甚至自体造血干细胞移植虽然提高了MM的缓解率并延长了患者的生存期,但最终均复发并对化疗产生耐药;而且随着化疗次数的增加预后愈差〔1〕。因此,难治复发性MM的治疗成为血液病中急需解决的难题之一。难治复发性MM患者年龄较大,一般状况差,而传统的VAD Multiple myeloma (MM) is the second most common tumor in the blood system, accounting for about 10%. The incidence of occult onset is high in middle-aged and elderly patients. Combined chemotherapy and even autologous hematopoietic stem cell transplantation improve the remission rate and prolong the rate of MM The patient’s survival, but eventually both recurrence and chemotherapy resistance; and with the increase in the number of chemotherapy prognosis worse (1). Therefore, the treatment of refractory recurrent MM become one of the problems to be solved urgently in the blood disease. Patients with refractory recurrent MM are older, generally poor, and have a traditional VAD